Novartis | NVS - Pre Tax Profit


Novartis reported $5.17B in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
AbbVie USD 4.38B 1.92B Sep/2025
Amgen USD 3.92B 2.35B Sep/2025
AstraZeneca USD 3.24B 117M Sep/2025
Bausch Health Companies USD 218M 78M Sep/2025
Biogen USD 557.3M 186.7M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Canopy Growth CAD -1.42M 39.82M Sep/2025
Corcept Therapeutics USD 15.24M 16.45M Sep/2025
Drreddys Laboratories INR 15.43B 1.96B Dec/2025
Eli Lilly USD 7.23B 456M Sep/2025
Gilead Sciences USD 3.64B 1.21B Sep/2025
GlaxoSmithKline GBP 1.23B 1.23B Dec/2025
Glaxosmithkline GBP 2.46B 569M Sep/2025
J&J USD 4.97B 2.53B Dec/2025
Merck USD 6.74B 22M Sep/2025
Novartis USD 4.2B 335M Sep/2025
Novartis USD 5.17B 637M Sep/2025
Pacira USD 9.52M 11.45M Sep/2025
Perrigo USD 22.4M 19.2M Sep/2025
Pfizer USD 3.33B 290M Sep/2025
Phibro Animal Health USD 4.84M 4.78M Dec/2024
Prestige Brands USD 69.13M 7.35M Sep/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sanofi EUR -1.16B 5.5B Dec/2025
Sanofi EUR -1.16B 6.23B Dec/2025
Supernus Pharmaceuticals USD -1.91M 56.04M Dec/2025
Zoetis USD 887M 15M Sep/2025